BIO 11006

Drug Profile

BIO 11006

Alternative Names: BIO-11006; BIO-11006 Inhalation Solution

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator North Carolina State University
  • Developer BioMarck Pharmaceuticals
  • Class Antineoplastics; Expectorants; Peptides
  • Mechanism of Action Myristoylated alanine rich C kinase substrate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Clinical Phase Unknown Lung cancer
  • Preclinical Adult respiratory distress syndrome; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma

Most Recent Events

  • 13 Jul 2017 Biomarck Pharmaceuticals plans to initiate a phase IIa trial in Acute respiratory distress syndrome in USA (Inhalation) (NCT03202394)
  • 21 Apr 2017 Biomarck Pharmaceuticals in collaboration with Live Like Bella® Childhood Cancer Foundation plans a compassionate use trial for rhabdomyosarcoma amongst other types of childhood cancer
  • 21 Apr 2017 Biomarck Pharmaceuticals plans to initiate proof-of-efficacy phase I trials in lung cancer (Biomarck Pharmaceuticals pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top